Expanding Experience With Liver Transplantation in Acute Intermittent Porphyria

Affiliations

¹ Department of MedicineDivision of Gastroenterology, Hepatology and Nutrition University of Pittsburgh Medical Center Pittsburgh PA Department of Preventive Medicine and Population HealthDivision of Gastroenterology and Hepatology University of Texas Medical Branch Galveston TX Department of Internal MedicineDivision of Gastroenterology and Hepatology University of Texas Medical Branch Galveston TX.

Editorial

Akshata Moghe et al. Liver Transpl. 2021 Apr.

. 2021 Apr;27(4):477-478.

doi: 10.1002/lt.25979. Epub 2021 Feb 12.

¹ Department of MedicineDivision of Gastroenterology, Hepatology and Nutrition University of Pittsburgh Medical Center Pittsburgh PA Department of Preventive Medicine and Population HealthDivision of Gastroenterology and Hepatology University of Texas Medical Branch Galveston TX Department of Internal MedicineDivision of Gastroenterology and Hepatology University of Texas Medical Branch Galveston TX.

No abstract available

Comment on

Liver Transplantation for Acute Intermittent Porphyria.
Lissing M, Nowak G, Adam R, Karam V, Boyd A, Gouya L, Meersseman W, Melum E, Ołdakowska-Jedynak U, Reiter FP, Colmenero J, Sanchez R, Herden U, Langendonk J, Ventura P, Isoniemi H, Boillot O, Braun F, Perrodin S, Mowlem E, Wahlin S; European Liver and Intestine Transplant Association. Lissing M, et al. Liver Transpl. 2021 Apr;27(4):491-501. doi: 10.1002/lt.25959. Epub 2021 Jan 29. Liver Transpl. 2021. PMID: 33259654 Free PMC article.

1. Lissing M, Nowak G, Adam R, Karam V, Boyd A, Gouya L, et al. Liver transplantation for acute intermittent porphyria. Liver Transpl 2021;27:491–501.
1. Bonkovsky HL, Maddukuri VC, Yazici C, Anderson KE, Bissell DM, Bloomer JR, et al. Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium. Am J Med 2014;127:1233–1241.
1. Marsden JT, Guppy S, Stein P, Cox TM, Badminton M, Gardiner T, et al. Audit of the use of regular haem arginate infusions in patients with acute porphyria to prevent recurrent symptoms. JIMD Rep 2015;22:57–65.
1. Balwani M, Sardh E, Ventura P, Peiro PA, Rees DC, Stolzel U, et al. Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria. N Engl J Med 2020;382:2289–2301.
1. Tchernitchko D, Tavernier Q, Lamoril J, Schmitt C, Talbi N, Lyoumi S, et al. A variant of peptide transporter 2 predicts the severity of porphyria‐associated kidney disease. J Am Soc Nephrol 2017;28:1924–1932.